Details
Stereochemistry | RACEMIC |
Molecular Formula | C3H8O2 |
Molecular Weight | 76.0944 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CO
InChI
InChIKey=DNIAPMSPPWPWGF-UHFFFAOYSA-N
InChI=1S/C3H8O2/c1-3(5)2-4/h3-5H,2H2,1H3
Molecular Formula | C3H8O2 |
Molecular Weight | 76.0944 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.8 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4032274/ |
20.7 mg 3 times / day steady-state, oral dose: 20.7 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PROPYLENE GLYCOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.23 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4032274/ |
20.7 mg 3 times / day steady-state, oral dose: 20.7 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PROPYLENE GLYCOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.79 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4032274/ |
20.7 mg 3 times / day steady-state, oral dose: 20.7 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PROPYLENE GLYCOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.8 g/kg 1 times / day multiple, oral (mean) Dose: 0.8 g/kg, 1 times / day Route: oral Route: multiple Dose: 0.8 g/kg, 1 times / day Sources: |
unhealthy, 13 years n = 1 Health Status: unhealthy Condition: refractory myoclonic status epilepticus Age Group: 13 years Sex: M Population Size: 1 Sources: |
Other AEs: Distributive shock, Acidosis metabolic... |
20.7 g 3 times / day multiple, oral Dose: 20.7 g, 3 times / day Route: oral Route: multiple Dose: 20.7 g, 3 times / day Co-administed with:: sodium phenytoin(oral solution) Sources: |
unhealthy, 18 - 65 years n = 16 Health Status: unhealthy Age Group: 18 - 65 years Sex: M+F Population Size: 16 Sources: |
Other AEs: Mental disorder NOS... |
41.4 g 2 times / day multiple, oral Dose: 41.4 g, 2 times / day Route: oral Route: multiple Dose: 41.4 g, 2 times / day Co-administed with:: sodium phenytoin(oral solution) Sources: |
unhealthy, 18 - 65 years n = 6 Health Status: unhealthy Age Group: 18 - 65 years Sex: M+F Population Size: 6 Sources: |
Other AEs: Mental disorder NOS... |
8.64 g single, rectal |
healthy, adult n = 10 Health Status: healthy Age Group: adult Population Size: 10 Sources: |
|
173 mg/kg single, rectal Dose: 173 mg/kg Route: rectal Route: single Dose: 173 mg/kg Sources: |
healthy, children n = 4 Health Status: healthy Age Group: children Population Size: 4 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Acidosis metabolic | 0.8 g/kg 1 times / day multiple, oral (mean) Dose: 0.8 g/kg, 1 times / day Route: oral Route: multiple Dose: 0.8 g/kg, 1 times / day Sources: |
unhealthy, 13 years n = 1 Health Status: unhealthy Condition: refractory myoclonic status epilepticus Age Group: 13 years Sex: M Population Size: 1 Sources: |
|
Distributive shock | 0.8 g/kg 1 times / day multiple, oral (mean) Dose: 0.8 g/kg, 1 times / day Route: oral Route: multiple Dose: 0.8 g/kg, 1 times / day Sources: |
unhealthy, 13 years n = 1 Health Status: unhealthy Condition: refractory myoclonic status epilepticus Age Group: 13 years Sex: M Population Size: 1 Sources: |
|
Mental disorder NOS | severe, 1 patient | 20.7 g 3 times / day multiple, oral Dose: 20.7 g, 3 times / day Route: oral Route: multiple Dose: 20.7 g, 3 times / day Co-administed with:: sodium phenytoin(oral solution) Sources: |
unhealthy, 18 - 65 years n = 16 Health Status: unhealthy Age Group: 18 - 65 years Sex: M+F Population Size: 16 Sources: |
Mental disorder NOS | severe, 2 patients | 41.4 g 2 times / day multiple, oral Dose: 41.4 g, 2 times / day Route: oral Route: multiple Dose: 41.4 g, 2 times / day Co-administed with:: sodium phenytoin(oral solution) Sources: |
unhealthy, 18 - 65 years n = 6 Health Status: unhealthy Age Group: 18 - 65 years Sex: M+F Population Size: 6 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | yes (co-administration study) Comment: Can't find IC50/Ki values;Propylene glycol inhibited the activity of CYP2El as indicated by 84% reduction in the clearance of 3 mg/kg dose of chlorzoxazone |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/7479582/ Page: 4.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Practical production of (S)-1,2-propanediol and its derivative through baker's yeast-mediated reduction. | 2001 |
|
Enantiomeric separation of N-protected amino acids by non-aqueous capillary electrophoresis with dimeric forms of quinine and quinidine derivatives serving as chiral selectors. | 2002 Mar 1 |
|
Stereoselective oxidation of aliphatic diols and reduction of hydroxy-ketones with galactitol dehydrogenase from Rhodobacter sphaeroides D. | 2003 |
|
Freezing monolayers of cells without gap junctions. | 2003 Apr |
|
Vitrification of ECV304 cell suspensions using solutions containing propane-1,2-diol and trehalose. | 2003 Apr |
|
A practical and scaleable synthesis of A-224817.0, a novel nonsteroidal ligand for the glucocorticoid receptor. | 2003 Apr 18 |
|
[Study on the toxicological effect of chloropropanols on rats]. | 2003 Jul |
|
Alternative liquid chromatographic method for determination of the methoxyl and 2-hydroxypropoxyl content in cellulose ether derivatives. | 2003 Jul-Aug |
|
Cryopreservation of cornea: a low cooling rate improves functional survival of endothelium after freezing and thawing. | 2003 Jun |
|
Structural rationalization for the lack of stereospecificity in coenzyme B12-dependent diol dehydratase. | 2003 Jun 20 |
|
The epimeric 9-oxobicyclo[3.3.1]nonane-3-carboxylic acids: hydrogen-bonding patterns of the endo acid and the lactol of the exo acid. | 2003 Mar |
|
Determination of the dermal penetration of esterom components using microdialysis sampling. | 2003 Nov |
|
Enantiospecific synthesis of the phospholipase A2 inhibitors (-)-cinatrin C1 and (+)-cinatrin C3. | 2003 Oct 21 |
|
Protein content of polyhedral organelles involved in coenzyme B12-dependent degradation of 1,2-propanediol in Salmonella enterica serovar Typhimurium LT2. | 2003 Sep |
|
Conversion of 2-deoxy-D-ribose into 2-amino-5-(2-deoxy-beta-D-ribofuranosyl)pyridine, 2'-deoxypseudouridine, and other C-(2'-deoxyribonucleosides). | 2003 Sep 21 |
|
Effect of chronic ritonavir administration on pregnant rats and their fetuses. | 2004 |
|
Aglacins I-K, three highly methoxylated lignans from Aglaia cordata. | 2004 Apr |
|
Highly stereoselective intermolecular oxy-michael addition reaction to alpha,beta-unsaturated malonate esters. | 2004 Apr 29 |
|
Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. | 2004 Aug |
|
Sevoflurane promotes endothelium-dependent smooth muscle relaxation in isolated human omental arteries and veins. | 2004 Aug |
|
Chiral ligand exchange capillary electrophoresis using borate anion as a central ion. | 2004 Dec |
|
Vitrification of pronuclear-stage mouse embryos on solid surface (SSV) versus in cryotube: comparison of the effect of equilibration time and different sugars in the vitrification solution. | 2004 Feb |
|
Scintigraphic sign of functional biliary obstruction is pathognomic for sphincter of Oddi dysfunction. | 2004 Jan-Feb |
|
Simultaneous XRD-DSC measurements of water-2-propanol at sub-zero temperatures. | 2004 Jul |
|
In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation. | 2004 Jul |
|
Synthesis of optically pure (+)-puraquinonic acid and assignment of absolute configuration to natural (-)-puraquinonic acid. Use of radical cyclization for asymmetric generation of a quaternary center. | 2004 Jun 11 |
|
Expression of connexins in human preimplantation embryos in vitro. | 2004 Jun 2 |
|
Close association of endothelial dysfunction with insulin resistance and carotid wall thickening in hypertension. | 2004 Mar |
|
Fermentative production of chemicals that can be used for polymer synthesis. | 2004 Mar 15 |
|
Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines. | 2004 Mar 22 |
|
Glycosidase-inhibiting pyrrolidines and pyrrolizidines with a long side chain in Scilla peruviana. | 2004 May |
|
Unprovoked and glyceryl trinitrate-provoked head-up tilt table test is safe in older people: a review of 10 years' experience. | 2004 Nov |
|
Endothelial nitric oxide synthase and methylenetetrahydrofolate reductase gene polymorphisms are associated with endothelial dysfunction in young, healthy men. | 2004 Oct |
|
Highly stereoselective oxy-Michael additions to alpha,beta-disubstituted nitro olefins: asymmetric synthesis of pseudo-norephedrine derivatives and THP* protected alpha-hydroxy ketones. | 2004 Oct 21 |
|
Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors. | 2004 Sep |
|
Pregnancies and births after oocyte cryopreservation. | 2004 Sep |
|
Metabolites in ventricular cerebrospinal fluid detected by proton magnetic resonance spectroscopic imaging. | 2004 Sep |
|
Design of oligolactone-based scaffolds for bone tissue engineering. | 2005 |
|
Two (+)-alpha,4-dimethyl-2-oxocyclohexaneacetic acids: hydrogen bonding in a terpenoid gamma-keto acid and in a diastereomeric lactol. | 2005 Apr |
|
Design of low-toxic and temperature-sensitive anionic microemulsions using short propyleneglycol alkyl ethers as cosurfactants. | 2005 Aug 30 |
|
Pentane-1,5-diol as a percutaneous absorption enhancer. | 2005 Dec |
|
Identification of the 1,2-propanediol-1-yl radical as an intermediate in adenosylcobalamin-dependent diol dehydratase reaction. | 2005 Feb 15 |
|
A chemoenzymatic total synthesis of the undecenolide (-)-cladospolide B via a mid-stage ring-closing metathesis and a late-stage photo-rearrangement of the E-isomer. | 2005 Mar 21 |
|
Novel approach for classifying chemicals according to skin sensitizing potency by non-radioisotopic modification of the local lymph node assay. | 2005 Mar-Apr |
|
Are all aciclovir cream formulations bioequivalent? | 2005 Nov 4 |
|
Patch testing with patients' own cosmetics and toiletries--results of the IVDK*, 1998-2002. | 2005 Oct |
|
The diazo route to diazonamide A: studies on the tyrosine-derived fragment. | 2005 Oct 21 |
|
Virucidal activity of a new hand disinfectant with reduced ethanol content: comparison with other alcohol-based formulations. | 2006 Jan |
|
Bifunctional compounds eliciting anti-inflammatory and anti-cholinesterase activity as potential treatment of nerve and blister chemical agents poisoning. | 2006 Jan-Feb |
|
Modulation of the rheological and mucoadhesive properties of thermosensitive poloxamer-based hydrogels intended for the rectal administration of quinine. | 2006 Mar |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:47 GMT 2023
by
admin
on
Fri Dec 15 15:20:47 GMT 2023
|
Record UNII |
6DC9Q167V3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-1520
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
CFR |
21 CFR 184.1666
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
CFR |
21 CFR 589.1001
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
JECFA EVALUATION |
INS-1520
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
WHO-VATC |
QA16QA01
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
DSLD |
1156 (Number of products:1)
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
EPA PESTICIDE CODE |
68603
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
CFR |
21 CFR 349.12
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
CFR |
21 CFR 172.850
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
FDA ORPHAN DRUG |
98896
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
CFR |
21 CFR 582.4666
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
||
|
NCI_THESAURUS |
C82130
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4024
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL286398
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
57-55-6
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
6DC9Q167V3
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
100000078520
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
D019946
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
SUB107763
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
DB01839
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
m9238
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
16997
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
m9238
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
PROPYLENE GLYCOL
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | Description: A colourless, clear, and viscous liquid; odourless. Miscibility: Miscible with water and ethanol (~750 g/l) TS. Category: Solvent; humectant. Storage: Propylene glycol should be kept in a tightly closed container. Additional information: Propylene glycol is hygroscopic. Boiling range, 185-189 ?C. Identity test: Dissolve 0.1 mL in sufficient water to produce 100 mL, dilute 1 mL to 10 mL, and place 0.5 mL of this solution in a test-tube. Cool in ice, add 5 mL of a cooled mixture of 10 mL of water and 90 mL of sulfuric acid (~1760 g/l) TS, heat on a water-bath at 70 ?C for10 minutes, and cool again. Add 0.2 mL of triketohydrindene/sodium metabisulfite TS; a violet colour slowly appears. | ||
|
1030
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
200-338-0
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
SUB12566MIG
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
DTXSID0021206
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
174
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
34693
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | RxNorm | ||
|
C29388
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
PROPYLENE GLYCOL
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
69860
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
1576708
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY | |||
|
6DC9Q167V3
Created by
admin on Fri Dec 15 15:20:47 GMT 2023 , Edited by admin on Fri Dec 15 15:20:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Propylene Glycol(mg/cigarette)
Canadian = 1.7 SD(0.2)
Imported = 4.7 SD(0.0)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
no peak value listed in USP-NF
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
NO peak value listed in USP
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |